AKOYA BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.85 USD | -1.72% |
|
-33.18% | -41.60% |
| May. 15 | Piper Sandler Cuts Akoya Biosciences Price Target to $6 From $8, Maintains Overweight Rating | MT |
| May. 14 | Top Midday Decliners | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 108M | Sales 2025 * | 131M | Capitalization | 141M |
|---|---|---|---|---|---|
| Net income 2024 * | -51M | Net income 2025 * | -32M | EV / Sales 2024 * | 1.38 x |
| Net Debt 2024 * | 8.75M | Net cash position 2025 * | 7.29M | EV / Sales 2025 * | 1.02 x |
| P/E ratio 2024 * |
-2.6
x | P/E ratio 2025 * |
-4.72
x | Employees | 330 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.84% |
More Fundamentals
* Assessed data
More news
Latest transcript on Akoya Biosciences, Inc.
More recommendations
More press releases
| 1 day | -1.72% | ||
| 1 week | -33.18% | ||
| Current month | -25.39% | ||
| 1 month | -27.11% | ||
| 3 months | -52.18% | ||
| 6 months | -34.18% | ||
| Current year | -41.60% |
1 week
2.65
4.42
1 month
2.654.65
Current year
2.656.31
1 year
2.658.80
3 years
2.6523.44
5 years
2.6528.96
10 years
2.6528.96
| Managers | Title | Age | Since |
|---|---|---|---|
Brian McKelligon
CEO | Chief Executive Officer | 55 | 17-06-30 |
Johnny Ek
DFI | Director of Finance/CFO | 48 | 23-03-19 |
Pascal Bamford
CTO | Chief Tech/Sci/R&D Officer | - | 21-10-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Shepler
CHM | Chairman | 67 | 15-10-31 |
Myla Lai-Goldman
BRD | Director/Board Member | 66 | 21-09-15 |
| Director/Board Member | 67 | 19-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +11.05% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 2.85 | -1.72% | 403,078 |
| 24-05-16 | 2.9 | +3.94% | 650,782 |
| 24-05-15 | 2.79 | -3.79% | 677,999 |
| 24-05-14 | 2.9 | -29.61% | 2,214,378 |
| 24-05-13 | 4.12 | -3.40% | 162,138 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research, and diagnostics. It offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections, and tissue microarrays (TMAs).
Calendar
2024-06-04
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.85
USD
Average target price
7.429
USD
Spread / Average Target
+160.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -41.60% | 141M | |
| +12.15% | 227B | |
| +14.90% | 197B | |
| +18.22% | 141B | |
| +29.15% | 110B | |
| +0.53% | 64.15B | |
| +16.92% | 53.72B | |
| +6.33% | 51.75B | |
| +10.93% | 45.2B | |
| +5.87% | 37.37B |
- Stock Market
- Equities
- AKYA Stock
